[1]
N. Privšek and C. Grašič Kuhar, “Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer”, Onkologija, vol. 25, no. 2, pp. 48–53, Nov. 2021.